Natco Pharma has shared an update regarding the launch of the generic version of Risdiplam in India.
The company has received many questions from investors and patients about when the drug will be available, its price, and other details. To clarify, Natco said that the Delhi High Court had earlier rejected Roche’s request to stop Natco from launching the drug. However, Roche has now appealed this decision, and the higher court has asked both parties to maintain the current situation until a final decision is made.
Read More: Sun Pharma Rolls Out Revolutionary Acid Blocker FEXUCLUE in India
Because the case is still going on, Natco does not want to comment further. But the company made it clear that it will only launch the drug after getting a clear go-ahead from the higher court, which is expected soon.
Natco has decided to price the drug at an MRP of ₹15,900, which is in line with what it has told the court. The company also plans to support some patients with discounts through its patient access program.
